| Literature DB >> 29754817 |
Zong Wei1, Eiji Yoshihara1, Nanhai He1, Nasun Hah1, Weiwei Fan1, Antonio F M Pinto2, Timothy Huddy1, Yuhao Wang1, Brittany Ross1, Gabriela Estepa1, Yang Dai1, Ning Ding1, Mara H Sherman1, Sungsoon Fang1, Xuan Zhao1, Christopher Liddle3, Annette R Atkins1, Ruth T Yu1, Michael Downes4, Ronald M Evans5.
Abstract
A primary cause of disease progression in type 2 diabetes (T2D) is β cell dysfunction due to inflammatory stress and insulin resistance. However, preventing β cell exhaustion under diabetic conditions is a major therapeutic challenge. Here, we identify the vitamin D receptor (VDR) as a key modulator of inflammation and β cell survival. Alternative recognition of an acetylated lysine in VDR by bromodomain proteins BRD7 and BRD9 directs association to PBAF and BAF chromatin remodeling complexes, respectively. Mechanistically, ligand promotes VDR association with PBAF to effect genome-wide changes in chromatin accessibility and enhancer landscape, resulting in an anti-inflammatory response. Importantly, pharmacological inhibition of BRD9 promotes PBAF-VDR association to restore β cell function and ameliorate hyperglycemia in murine T2D models. These studies reveal an unrecognized VDR-dependent transcriptional program underpinning β cell survival and identifies the VDR:PBAF/BAF association as a potential therapeutic target for T2D.Entities:
Keywords: BAF complex; BRD9; CRISPR screening; PBAF complex; VDR; chromatin remodeling; diabetes; inflammation; nuclear receptor; β cell
Mesh:
Substances:
Year: 2018 PMID: 29754817 PMCID: PMC5987229 DOI: 10.1016/j.cell.2018.04.013
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582